BACKGROUND AND AIMS: Epidemiological data have recently emerged to suggest Helicobacter pylori may protect against certain chronic inflammatory diseases such as inflammatory bowel disease (IBD). However, the mechanism for the observed inverse association between H pylori and IBD has not been described. METHODS: The frequency of immunoregulatory (IRS) to immunostimulatory (ISS) sequences within the genome of various bacteria was calculated using MacVector software. The induction of type I IFN and IL-12 responses by DNA-pulsed murine bone marrow-derived dendritic cells (BMDC) and human plasmacytoid dendritic cells (DC) was analysed by cytokine production. The effect of H pylori DNA on Escherichia coli DNA production of type I IFN and IL-12 was assessed. The in-vivo significance of H pylori DNA suppression was assessed in a dextran sodium sulphate (DSS) model of colitis. The systemic levels of type I IFN were assessed in H pylori-colonised and non-colonised patients. RESULTS: H pylori DNA has a significantly elevated IRS:ISS ratio. In-vitro experiments revealed the inability of H pylori DNA to stimulate type I IFN or IL-12 production from mouse BMDC or human plasmacytoid DC. H pylori DNA was also able to suppress E coli DNA production of type I IFN and IL-12. The administration of H pylori DNA before the induction of DSS colitis significantly ameliorated the severity of colitis compared with E coli DNA or vehicle control in both an acute and chronic model. Finally, the systemic levels of type I IFN were found to be lower in H pylori-colonised patients than non-colonised controls. CONCLUSIONS: This study indicates that H pylori DNA has the ability to downregulate pro-inflammatory responses from DC and this may partly explain the inverse association between H pylori and IBD.
BACKGROUND AND AIMS: Epidemiological data have recently emerged to suggest Helicobacter pylori may protect against certain chronic inflammatory diseases such as inflammatory bowel disease (IBD). However, the mechanism for the observed inverse association between H pylori and IBD has not been described. METHODS: The frequency of immunoregulatory (IRS) to immunostimulatory (ISS) sequences within the genome of various bacteria was calculated using MacVector software. The induction of type I IFN and IL-12 responses by DNA-pulsed murine bone marrow-derived dendritic cells (BMDC) and human plasmacytoid dendritic cells (DC) was analysed by cytokine production. The effect of H pylori DNA on Escherichia coli DNA production of type I IFN and IL-12 was assessed. The in-vivo significance of H pylori DNA suppression was assessed in a dextran sodium sulphate (DSS) model of colitis. The systemic levels of type I IFN were assessed in H pylori-colonised and non-colonised patients. RESULTS:H pylori DNA has a significantly elevated IRS:ISS ratio. In-vitro experiments revealed the inability of H pylori DNA to stimulate type I IFN or IL-12 production from mouse BMDC or human plasmacytoid DC. H pylori DNA was also able to suppress E coli DNA production of type I IFN and IL-12. The administration of H pylori DNA before the induction of DSS colitis significantly ameliorated the severity of colitis compared with E coli DNA or vehicle control in both an acute and chronic model. Finally, the systemic levels of type I IFN were found to be lower in H pylori-colonised patients than non-colonised controls. CONCLUSIONS: This study indicates that H pylori DNA has the ability to downregulate pro-inflammatory responses from DC and this may partly explain the inverse association between H pylori and IBD.
Authors: A Krug; S Rothenfusser; V Hornung; B Jahrsdörfer; S Blackwell; Z K Ballas; S Endres; A M Krieg; G Hartmann Journal: Eur J Immunol Date: 2001-07 Impact factor: 5.532
Authors: Daniel Falush; Thierry Wirth; Bodo Linz; Jonathan K Pritchard; Matthew Stephens; Mark Kidd; Martin J Blaser; David Y Graham; Sylvie Vacher; Guillermo I Perez-Perez; Yoshio Yamaoka; Francis Mégraud; Kristina Otto; Ulrike Reichard; Elena Katzowitsch; Xiaoyan Wang; Mark Achtman; Sebastian Suerbaum Journal: Science Date: 2003-03-07 Impact factor: 47.728
Authors: Peter D R Higgins; Laura A Johnson; Jay Luther; Min Zhang; Kay L Sauder; Luz P Blanco; John Y Kao Journal: Inflamm Bowel Dis Date: 2010-10-25 Impact factor: 5.325
Authors: Katryn J Stacey; Greg R Young; Francis Clark; David P Sester; Tara L Roberts; Shalin Naik; Matthew J Sweet; David A Hume Journal: J Immunol Date: 2003-04-01 Impact factor: 5.422
Authors: H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch Journal: Gut Date: 2003-12 Impact factor: 23.059
Authors: Marta Maia Bosca-Watts; Joan Tosca; Rosario Anton; Maria Mora; Miguel Minguez; Francisco Mora Journal: World J Gastrointest Pathophysiol Date: 2015-02-15
Authors: Adam Tepler; Neeraj Narula; Richard M Peek; Anish Patel; Cyrus Edelson; Jean-Frederic Colombel; Shailja C Shah Journal: Aliment Pharmacol Ther Date: 2019-06-05 Impact factor: 8.171
Authors: Mathias Oertli; Manuel Noben; Daniela B Engler; Raphaela P Semper; Sebastian Reuter; Joachim Maxeiner; Markus Gerhard; Christian Taube; Anne Müller Journal: Proc Natl Acad Sci U S A Date: 2013-02-04 Impact factor: 11.205
Authors: Matthew G Varga; M Blanca Piazuelo; Judith Romero-Gallo; Alberto G Delgado; Giovanni Suarez; Morgan E Whitaker; Uma S Krishna; Rachna V Patel; Eric P Skaar; Keith T Wilson; Holly M S Algood; Richard M Peek Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-10-06 Impact factor: 4.052